Property:Results after intervention
This is a property of type Text.
S
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
NA +
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) +
NA +
Stratton et al. (2010): Oral Selenium Supplementation Has No Effect on Prostate- Specific Antigen Velocity in Men Undergoing Active Surveillance for Localized Prostate Cancer +
After 5 years: selenium arms not significantly different to placebo arm (p=0.32 and p=0.61) or to each other
Subgroup of high-selenium arm with high selenium value at baseline shows higher PSA values than placebo arm (p=0.018) +
Su et al. (2004): Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms +
NA +
Su et al. (2004): Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms +
NA +
Su et al. (2004): Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms +
NA +
Su et al. (2004): Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms +
NA +
Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy +
At 12 weeks:
Full analysis set: no difference between arms
PP analysis: less fatigue/improvement of symptoms in intervention compared to placebo arm (intervention: 41.1%, placebo: 25%; χ² = 5.936; p = 0.015); Overall p = 0.0135 +
Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy +
Full analysis set:
Significant differences between arms at all time points with more improvement in intervention arm:
12 weeks (4 weeks after intervention): Intervention: 57.8%, Placebo: 39.7%; χ² = 7.406; p = 0.007
But no difference of ≥1 grade between arms.
As well as an overall significantly steeper improvement in intervention arm (p < 0.05) compared to placebo arm +
Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy +
NA +
Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy +
At 12 weeks:
In full analysis set and PP-analysis significant change from baseline (p < 0.01, no further data shown). +
T
Tan et al. (2018): Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor +
The comparison of quality of life for the two arms showed that the enzyme arm scored better than the control arm in all items:
Items in enzyme arm; control arm:
Food: 5.76(2.78); 7.96(2.18) p=0.0004
Language: 1.17(0.63); 2.57(0.93) p<0.0001
Feeling: 0.83(0.36); 1.44(0.76) p<0.0001
Swelling: 3.28(1.57); 4.76(2.06) p=0.0010
Pain: 4.16(2.01); 6.23(1.01) p<0.0001
Nausea: 0.21(0.12); 0.91(0.21) p<0.0001
Daily living: 1.38(0.34); 3.38(0.54) p<0.0001 +
Tan et al. (2018): Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor +
The enzyme arm exhibited significantly lower scores than the control arm at each time point. +
Tan et al. (2018): Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor +
The enzyme arm exhibited significantly lower scores at each time point compared to the control arm (p=0.013-0.044) +
Tan et al. (2018): Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor +
The enzyme arm exhibited significantly lower swelling than the control arm at each time point (p<0.0001). +
Thamlikitkul et al. (2017): Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study +
NA +
Thamlikitkul et al. (2017): Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study +
NA +
Thamlikitkul et al. (2017): Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study +
No study-treatment-related adverse events were observed;
No significant difference in the incidence of adverse events between subjects receiving ginger and placebo.
Side effects - Intervention in n:
Fever: n = 4, Fatigue: n = 25, Muscosites: n = 5, Diarrhea: n = 2, Constipation: n = 14, Neutropenia: n = 6, Thrombcytopenia: n = 14
Side effects - Placebo in n:
Fever: n = 3, Fatigue: n = 21, Mucositis: n = 4, Constipation: n = 12, Neutropenia: n = 4, Thrombcytopenia: n = 12, Febrile neutropenia: n = 1
no significant differences +
Thamlikitkul et al. (2017): Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study +
NA +
Thamlikitkul et al. (2017): Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study +
Chemotherapy intervention vs. placebo: Dose reduction: 3% vs. 3%
Delay: 9% vs. 6%
No p-values have been reported. +